Co-Diagnostics, Inc. (CODX) Q1 2025 Earnings Call Transcript
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Cath and I will be your conference operator today.
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Misses Revenue Estimates
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.31 per share a year ago.
All You Need to Know About CoDiagnostics (CODX) Rating Upgrade to Buy
CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.
Co-Diagnostics, Inc. (CODX) Q4 2024 Earnings Call Transcript
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Andrew Benson - IR Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Operator Good day, and welcome to the Co-Diagnostics Fourth Quarter and Full Year 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version
On Friday, Co-Diagnostics, Inc. CODX withdrew its FDA 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro in favor of submitting an enhanced version of the test for 510(k) clearance.
Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations. Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Jade Montgomery - H.C.
Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Tops Revenue Estimates
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.20 per share a year ago.
Co-Diagnostics, Inc. (CODX) Q2 2024 Earnings Call Transcript
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Jade Montgomery - H.C. Wainwright Operator Good day, and welcome to the Co-Diagnostics Second Quarter 2024 Earnings Conference Call.
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Tops Revenue Estimates
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.31 per share a year ago.
